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Background and purpose: The effectiveness and safety of edoxaban 60 mg and 30 mg for stroke 
prevention compared with warfarin in patients with atrial fibrillation (AF) has not been well-
described in a nationwide cohort of Caucasian patients treated in standard clinical practice.
Methods: We used Danish nationwide registries to identify patients with AF during June 2016 and 
November 2018 who were treated with edoxaban or warfarin and computed rates per 100 person-
years of thromboembolic, all-cause mortality, and bleeding events using an inverse probability of 
treatment weighting approach to account for baseline confounding. We used weighted pooled 
logistic regression to compute hazard ratios (HRs) with 95% confidence intervals (CIs) comparing 
events between edoxaban 60 mg and warfarin users; edoxaban 30 mg was not included in formal 
comparisons.
Results: We identified 6451 AF patients, mean age was 72 years and 40% were females. A total of 
1772 patients were treated with edoxaban 60 mg, 537 with edoxaban 30 mg, and 4142 with 
warfarin. The median CHA2DS2-VASc score was similar between warfarin and edoxaban 60 mg 
with a score of 3 (interquartile range [IQR] 2-4). In the inverse probability of treatment-weighted 
pseudo-population, the thromboembolic event rate for edoxaban 60 mg was 0.95 and 1.0 for 
warfarin, corresponding weighted HR of 1.00 (95% confidence intervals [CI] 0.59, 1.71). Edoxaban 
60 mg users were associated with lower rates of all-cause mortality (3.93) compared to warfarin 
(6.04), with a HR of 0.64 (95% CI 0.47 to 0.88). The event rates for bleeding were 3.36 and 3.14, 
respectively; HR 1.09 (95% CI 0.77, 1.57)
Conclusion: Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke 
prevention in routine clinical care for white European patients with AF, with non-significantly 
different risks for stroke and clinically relevant bleeding, but lower all-cause mortality.
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Non-standard Abbreviations and Acronyms 
AF: Atrial fibrillation
OAC: Oral anticoagulant
DOAC: Direct oral anticoagulants
CI: Confidence intervals
CHA2DS2-VASc: Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke, Vascular disease, 
Sex category 
eGFR: estimated glomerular filtration rate
HAS-BLED: Hypertension, Abnormal liver or renal function, Stroke, Bleeding, Labile INR, 





LVD: Left ventricular dysfunction
NSAID: Nonsteroidal anti-inflammatory drugs
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Atrial fibrillation (AF) affects more than 44 million individuals worldwide 1, and patients with AF 
are at several-fold increased risk of stroke compared with individuals without AF 1. Oral 
anticoagulant (OAC) therapy is effective for reducing the risk of stroke 2.
The direct oral anticoagulants (DOACs) continuously replace vitamin K-antagonists for stroke 
prevention in AF 3–7. Despite similar indications, the individual DOACs have important differences 
including renal excretion and liver metabolism, once daily vs twice daily dosing, and indications for 
dose reductions 8. 
Edoxaban was marketed in Denmark in June 2016, which was up to four years later than other 
DOACs. In the ENGAGE AF-TIMI 48 trial, the two edoxaban one daily dose regimes (30 mg and 
60 mg) was noninferior compared with warfarin (dose adjusted) for prevention of stroke or systemic 
embolism, and was additionally associated with significantly lower bleeding rates 9. Meta-analyses 
of randomized controlled trials have shown similar results 10–12. Observational studies evaluating 
the effectiveness and safety of edoxaban in standard clinical practice compared with warfarin have 
been conducted primarily in Asian AF populations 13,14, with limited data from Europe. 
We therefore used Danish nationwide registries to compare the effectiveness and safety of 
edoxaban with warfarin for stroke prevention in a cohort of patients with AF. 
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This was an observational cohort study based on registry data of Danish residents who claimed a 
prescription of warfarin or edoxaban between June 2016 and November 2018. Please see 
supplemental Table 1 and supplemental methods for details on data sources.
Study population and exposure
Individuals with a record of claiming a prescription of edoxaban or warfarin for stroke prevention 
after AF diagnosis between June 2016 through December 2018 was considered for inclusion. 
Individuals were screened for a hospital diagnosis (inpatient or outpatient) of AF before the first 
prescription claim or up to 30 days after. Patients with a record of mitral stenosis or heart valve 
replacement were excluded. Similarly, patients with an estimated glomerular filtration rate (eGFR; 
using the Chronic Kidney Disease Epidemiology Collaboration formula) <15 ml/min/1.73m2, 
dialysis treatment, or chronic kidney disease were excluded. Patients identified as receiving 
continuous warfarin treatment at the time of study start were excluded. Finally, we excluded 
patients with a record of an outcome event within the first month after first OAC prescription to 
ensure that outcomes would occur under the studied treatment exposure. The index date was 
therefore defined at the time of treatment initiation, while outcome analyses commenced 30 days 
after first prescription claim.
The study population was stratified according to first treatment claim, i.e. warfarin, edoxaban 60 
mg, or edoxaban 30 mg. Patients claiming a prescription were assumed in continuous treatment 
throughout follow-up. 
Comorbidities and comedications
We obtained information from the Danish registries on history of comorbidities at index date. Use 
of medication within 365 days before index. We combined covariate information into modified 
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HAS-BLED scores (the L component of labile INR values was not included) as a measure of 
baseline bleeding risk, and CHA2DS2-VASc scores to ascertain the risk of stroke in individuals. The 
Danish National Laboratory Registry was used to categorize renal function measured by (eGFR); 
the most recent available measurement was included in this characterization: the median time from 
index date to most recent measurement was 7 days, interquartile range (IQR) 2 to 39 days. 
Endpoints and follow-up
The study cohort was followed in the registries for up to two years. Only hospital-based primary 
diagnoses were included for outcome analyses to increase the validity of the coded diagnoses. The 
primary effectiveness outcome of thromboembolism was comprised by a composite of ischemic 
stroke, unspecified stroke, and systemic embolism. The safety outcomes were a composite endpoint 
of clinically relevant bleedings events leading to hospital contact, including intracranial bleeding, 
gastrointestinal bleeding, and major bleeding in other anatomic sites. All-cause mortality was 
investigated as an independent endpoint, since some of the studied outcomes may be fatal and 
therefore not recorded with diagnosis code at the hospital. All patients were followed from the 
index date to ascertain thromboembolism or bleeding events, with censoring at emigration, death (if 
not the outcome), or 31 December 2018, whichever came first.
Statistical analysis
Descriptive characteristics at the index date were provided as proportions for discrete variables and 
means and standard deviations (SD) for continuous variables. We calculated event rates as the 
number of events divided by person-time stratified by treatment exposure group.
Because of the non-randomized study design, differences in prognostic factors between exposure 
groups may bias the comparative treatment effectiveness and safety estimates. The analytic 
approach to establish comparative cohorts was based on an inverse probability treatment weighting 
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approach, as done previously 15. The weights were obtained using boosted regression trees 
including the following covariates to predict treatment exposure groups: sex, age (continuous), 
eGFR (continuous), ischemic heart disease, previous intracerebral bleeding, heart failure, diabetes, 
hypertension, prior thromboembolic event, vascular disease, use of statin or aspirin within the last 
year, a cancer diagnosis within last three years, and OAC experience status (binary). 
When inspecting the propensity scores for sufficient overlap, we observed poor overlap for 
edoxaban 30 mg vs the other two treatment alternatives. Post-hoc, we therefore decided not to 
include edoxaban 30 mg in the formal comparative effectiveness and safety analyses. However, to 
allow for comparison of warfarin vs edoxaban 30mg, we conducted an unplanned propensity score 
matched analysis. Specifically, we estimated the average treatment effect among the edoxaban 
30mg treated patients vs a matched group of warfarin users (control). Additional details and results 
are reported in supplemental materials.
The comparative effectiveness and safety analysis of edoxaban 60 mg vs. warfarin was based on the 
intention to treat approach, and contrasts between exposure groups were estimated by means of 
weighted pooled logistic regression models 16. The calculated weights were applied to ascertain the 
average treatment effect in the population and reported as hazard ratios (HRs) with warfarin being 
the reference. In detail, we fit weighted pooled logistic regressions including a categorical variable 
for treatment groups, and months of follow-up as a linear and a quadratic term. The survival curves 
depict the hypothetical situation had the entire population received warfarin treatment and had the 
entire population received edoxaban 60 mg 17. Please see supplemental information for additional 
details on the modelling approach and description on sensitivity analyses.
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We identified a total of 16960 patients who initiated edoxaban or warfarin during 2016 through 
November 2018. After applying exclusion criteria, 6451 were eligible for the study: 4142 were 
treated with warfarin, 1772 with edoxaban 60 mg, and 537 with edoxaban 30 mg (see supplemental 
Figure 1). The population mean age was 72 years and 40% were females. The baseline 
characteristics from the unweighted cohort are shown in Table 1. The median CHA2DS2-VASc 
score was similar between warfarin and edoxaban 60 mg with a score of 3 (IQR 1-3), but higher 
among edoxaban 30 mg, median score of 4 (IQR 3-6). The eGFR was markedly lower among 
edoxaban 30 mg users, with a mean eGFR of 53.3 ml/min/1.73m2 After applying IPTW, the 
baseline differences in the pseudo-population were minor when comparing warfarin and edoxaban 
60 mg, and absolute standardized differences were less than 0.1 for all measured covariates.
Risk of thromboembolism
During follow-up, we observed a total of 89 thromboembolic events: 60 among warfarin users, 21 
for edoxaban 60 mg, and 8 among edoxaban 30 mg (Table 2). The corresponding crude 
(unweighted) event rates per 100 person-years were 0.97, 1.25, and 1.66, respectively. 
In the IPTW pseudo-population, event rates were 1.0 for warfarin and 0.95 for edoxaban 60 mg. 
The median follow-up time was 10 months (IQR 5-16) for warfarin a d 7 months (IQR 4-12) for 
edoxaban 60 mg. The comparative effectiveness analysis comparing warfarin with edoxaban 60 mg 
showed a similar risk for thromboembolism with a HR of 1.00 (95% confidence intervals [CI] 0.59 
to 1.71). Figure 1 shows the standardized survival curves free from thromboembolic events 
representing what would have occurred had the entire population received either of the two 
treatment options.
All-cause mortality
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All-cause mortality was the most common outcome in the study population with an overall rate of 
6.69 (total of 560 deaths). All-cause mortality was markedly higher among edoxaban 30 mg users 
with a rate of 19.54, while it was 6.45 for warfarin, and 3.86 for edoxaban 60 mg.
Comparative analyses showed that edoxaban 60 mg had a lower risk compared to warfarin, HR of 
0.65 (95% CI 0.47 to 0.88) (Table 2). Of note, the risk of all-cause mortality visualized in Figure 2 
showed the two curves separating early, but also that the absolute risk of events differed little 
despite the statistically significant HR. Analyzing the composite outcome of all-cause mortality and 
thromboembolism resulted in a HR of 0.71 (95% CI 0.54 to 0.95).
Risk of bleeding 
We observed a total of 256 clinically relevant bleeding events during two years of follow-up: 188 
events among warfarin users, 55 for edoxaban 60 mg, and 13 for edoxaban 30 mg. The event rates 
for bleeding outcomes were 3.12 for warfarin, 3.33 for edoxaban 60 mg, and 2.71 for edoxaban 30 
mg (Table 2). Intracranial bleeding events were rare with event rates below 0.40, and the event rate 
for gastrointestinal bleeding was 1.27 (see Supplemental Table 2).
In the weighted cohort of warfarin vs edoxaban 60 mg, the event rates for bleeding were 3.14 and 
3.36, respectively. The HR from the comparative safety analysis was 1.09 (95% CI 0.77 to 1.57). 
Figure 3 shows the standardized bleeding free survival curves for both treatment options.
Subgroup analyses
Detailed results from all subgroup analyses are presented in Supplemental Table 3. Among OAC 
naïve patients, the risk of thromboembolism mirrored the main analysis with a HR of 0.99 (95% CI 
0.47 to 2.08) and similarly for the bleeding outcome with a HR of 1.10 (95% CI 0.71 to 1.71), and 
all-cause mortality, HR of 0.58 (95% CI 0.37 to 0.89). 
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Among patients age 75 years or older, the mean age was 82 years (SD 5.0) among warfarin users 
and 81 years (SD 5.0) among edoxaban 60 mg users. The HRs for thromboembolism and all-cause 
mortality was similar to the main analysis, and the (non-significant) HR for bleeding was 1.42 (95% 
CI 0.89 to 2.28).
Restriction to  patients at very high stroke risk, i.e. a CHA2DS2-VASc score of 4 or higher, there 
was a non-significant higher hazard for thromboembolism among edoxaban 60 mg users: HR of 
1.22 (95% CI 0.66 to 2.26), while HRs for all-cause mortality and bleeding were similar as reported 
in the main analysis.
In the subgroup of patients with some degree of affected renal function, the mean eGFR was 66.2 
ml/min/1.73m2 (SD 17.1) among warfarin users, and 71.5 ml/min/1.73m2 (SD 11.98) among 
edoxaban 60 mg users. The relative risk of comparative outcomes was similar to that of the main 
analysis.
Sensitivity analyses
Overall, the obtained results remained robust when analyzed in different analytic approaches. When 
restricting the outcome of bleeding events to primary diagnoses leading to hospitalization, the 
number of events were lower in the two exposure groups, but the HR was consistent with the main 
analysis: HR of 1.06 (95% CI 0.77 to 1.47). Examining competing risk of death on the outcome of 
thromboembolism did not change our treatment effectiveness estimates [data not shown]. In the 
exploratory analysis, risk factors strongly associated with all-cause mortality were heart failure and 
a cancer diagnosis within the last three years. When performing an additional post-hoc analysis 
restricting the population to patients without these clinical characteristics, this did not materially 
change the HR point estimate for all-cause mortality comparing warfarin and edoxaban 60 mg, HR 
of 0.73 (95% CI 0.48 to 1.10). The formal comparative outcome analyses between edoxaban 30mg 
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vs warfarin using propensity score matching are reported in supplemental materials: supplemental 
Figure 2 displays the propensity score overlap after matching, and supplemental Table 4 summaries 
patient characteristics in the matched cohort. The propensity score match HR of thromboembolism 
was 1.25 (95% CI 0.43 to 2.96); HR for bleeding was 0.57 (95% CI 0.28 to 1.15); and all-cause 
mortality HR was 1.33 (95% CI 0.96 to 1.83), please see supplemental Figure 3-5 for standardized 
survival curves for each outcome.
DISCUSSION
In this large, nationwide comparative effectiveness and safety study of edoxaban vs. warfarin for 
stroke prevention in Danish routine clinical care for patients with AF, we found that edoxaban 60 
mg was a safe and effective treatment compared with warfarin, with non-significantly different risks 
for stroke and clinically relevant bleeding, but lo er all-cause mortality and the composite outcome 
of ‘all-cause mortality and thromboembolism’. This was evident irrespective of various sensitivity 
analyses.
The observed thromboembolic event rates and relative risks are largely comparable with previous 
studies documenting comparable effectiveness of edoxaban for stroke prevention in AF 9,10,12. For 
example, a meta-analysis of randomized trials demonstrated similar relative risk for stroke (relative 
risk (RR) =1.00, 95% CI: 0.90-1.11), systemic embolic events (RR=1.00, 95% CI: 0.67 to 1.49), 
and adverse bleeding events (RR= 1.00, 95% CI: 0.91 to 1.0) 12. Bleeding rates per 100 person-
years in our study were also similar at 3.36 for edoxaban 60 mg and 3.14 for warfarin. Bleeding 
associated with edoxaban in standard clinical practice has been shown to mainly consist of minor or 
clinical relevant non major bleeding 18. We also demonstrated similar bleeding risks in our 
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sensitivity analysis restricted to bleeding events leading to hospitalization, HR of 1.06 (95% CI 0.77 
to 1.47) compared with the relative risk of 0.90 (95% CI 0.82 to 0.98) in the ENGAGE-AF-TIMI 48 
trial comparing edoxaban with warfarin 19.
In the present study, we show a significant reduction in all-cause mortality and the composite of 
‘all-cause mortality and thromboembolism’. In the historical randomized trials, warfarin reduced 
all-cause mortality by 26% compared to placebo/control and in the meta-analysis by Ruff et al. of 
the randomized trials, DOACs were associated with 10% lower mortality compared to those 
allocated to warfarin 20,21. In the randomized trials, outcome events are adjudicated by an events 
committee and cerebral scanning or post-mortems used to confirm a stroke diagnosis. In data 
obtained from routine clinical practice, there is rarely adjudication of events, nor mandatory 
postmortems, so some deaths could be due to (undiagnosed) fatal strokes.  
Rates of intracranial hemorrhage was generally low in both edoxaban and warfarin treated patients. 
In the randomized trials, there was a clear class-effect of DOACs with significant reduction in 
intracranial hemorrhage compared with warfarin 21, an observation supported by numerous studies 
based on data from routine clinical practice 22,23. Hence, the low risk of clinically relevant bleeding 
or intracranial hemorrhage, and our reduction of the composite of ‘all-cause mortality and 
thromboembolism’ supports the beneficial effectiveness and safety profile of edoxaban. 
Our data are generally consistent with real world data from Asia, showing better effectiveness and 
safety with edoxaban compared to warfarin as well as improved safety compared to some DOACs 
24. 
Strengths and Limitations
Our study was based on a large, nationwide cohort of patients with AF and a prescription for 
edoxaban or warfarin who were treated in a uniformly organized healthcare system. Our ability to 
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identify patients in these registries, in a national setting with free access to health care, and to track 
individuals enabled unselected patient inclusion and complete follow-up 25.
Due to the registry-based study design, we lacked information on drug adherence and persistence, 
quality of VKA treatment. Therefore, and by design, the study could not inform on outcomes based 
on an on-treatment analytic strategy. Our comparative analysis was based on weighted populations, 
which accounted only for observed imbalances between the treatment groups. For bleeding events, 
we used hospital diagnoses without specification of extent and severity of the bleeding events, and 
the validity of bleeding codes in the DNPR may vary with bleeding side and severity 26.
Conclusion
Edoxaban 60 mg is a safe and effective treatment compared with warfarin for stroke prevention in 
routine clinical care for Danish (mainly Caucasian) patients with AF, with non-significantly 
different risks for stroke and clinically relevant bleeding, but lower all-cause mortality and the 
composite of all-cause mortality and thromboembolism with edoxaban 60 mg.
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Table 1: Characteristics of patients with atrial fibrillation according to treatment regimen with 
warfarin (dose adjusted), edoxaban 60 mg, and edoxaban 30 mg.
Patient characteristics Warfarin Edoxaban 60 mg Edoxaban 30 mg
No. 4142 1772 537
Women % (N) 38.1 (1577) 38.6 (684) 64.6 (347)
Age, mean (SD) 70.6 (12.0) 72.2 (9.5) 82.8 (8.2)
Ischemic stroke 9.0 (371) 10.4 (185) 16.0 (86)
Hypertension 55.7 (2309) 60.2 (1066) 67.6 (363)
Heart failure or LVD 26.8 (1108) 22.3 (396) 40.2 (216)
Diabetes 15.5 (640) 16.0 (284) 18.4 (99)
Ischemic heart disease 24.3 (1005) 22.9 (406) 31.3 (168)
Intracranial bleeding 0.9 (38) 1.0 (18) 1.1 (6)
Gastrointestinal 
bleeding
3.2 (134) 3.3 (58) 4.5 (24)
Median CHA2DS2-
VASc score (IQR)
3.0 (2.0-4.0) 3.0 (2.0-4.0) 4.0 (3.0-5.0)
Score 0-2 43.3 (1795) 39.3 (696) 8.6 (46)
Score 3-5 47.8 (1979) 53.4 (946) 68.2 (366)
Score >5 8.9 (368) 7.3 (130) 23.3 (125)
Median HAS BLED 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (2.0-3.0)
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Score 0-1 33.6 (1390) 26.7 (474) 18.2 (98)
Score 2-3 55.0 (2278) 62.8 (1113) 64.4 (346)
Score >3 11.4 (474) 10.4 (185) 17.3 (93)
Cancer (ever) 18.6 (772) 21.0 (373) 27.7 (149)
Cancer diagnosed 
within 3 years




72.2 (20.1) 75.5 (14.5) 53.3 (18.9)
Medication
OAC naïve 69.6 (2883) 46.0 (815) 36.3 (195)
Warfarin 0 33.0 (584) 41.0 (220)
Apixaban 8.8 (364) 4.0 (70) 5.0 (27)
Dabigatran 6.4 (267) 6.4 (114) 6.0 (32)
Rivaroxaban 11.7 (485) 5.2 (93) 5.0 (27)
Aspirin 25.9 (1073) 19.9 (353) 22.0 (118)
Clopidogrel 9.1 (375) 7.6 (135) 9.9 (53)
Proton-pump 
inhibitors
29.5 (1222) 29.0 (513) 33.0 (177)
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Beta blocker 67.3 (2786) 65.6 (1163) 70.0 (376)
Non-loop diuretic 33.0 (1366) 35.3 (625) 44.1 (237)
Calcium channel 
blocker
27.8 (1152) 31.7 (561) 33.0 (177)
Renin-angiotensin 
inhibitor
48.2 (1998) 51.6 (914) 55.1 (296)
NSAID 19.5 (809) 16.8 (298) 9.5 (51)
SD: Standard deviation. IQR: Interquartile range. LVD: Left ventricular dysfunction. OAC: Oral 
anticoagulant. NSAID: Nonsteroidal anti-inflammatory drugs.
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Thromboembolism 89 83.13 1.07
Edoxaban 60 mg
21 16.75 1.25 0.95 1.00 
(0.59 to 1.71)
Warfarin 60 61.55 0.97 1.00 Reference
Bleeding 256 81.64 3.14
Edoxaban 60 mg
55 16.50 3.33 3.36 1.09
(0.77 to 1.57)
Warfarin 188 60.34 3.12 3.14 Reference
All-cause mortality 560 83.72 6.69
Edoxaban 60 mg
65 16.85 3.86 3.93 0.64
(0.47 to 0.88)
Warfarin 400 62.00 6.45 6.04 Reference
IPT: Inverse probability treatment. CI: Confidence intervals.
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Figure 1: Standardized event free survival curves of thromboembolism 
332x233mm (96 x 96 DPI) 
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Figure 2: Standardized survival curves for all-cause mortality 
330x233mm (96 x 96 DPI) 
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Figure 3: Standardized event free survival curves of bleeding outcome 
330x235mm (96 x 96 DPI) 
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